Introduction
The c-myb proto-oncogene is the founding member of a family of genes, consisting of A-myb, B-myb, and c-myb, which encode transcription factors that regulate the expression of genes important for lineage determination, cell proliferation and differentiation.
1,2 c-myb is expressed predominantly in the hematopoietic system and a large body of evidence, involving c-myb null and conditional knock-out mice, and the analysis of hypomorphic c-myb alleles, has demonstrated essential roles for c-myb in the development of most hematopoietic lineages. [3] [4] [5] [6] [7] [8] c-myb expression is highest in the immature progenitors of all hematopoietic lineages, and downregulation of its expression is an essential prerequisite for their terminal differentiation. Although initially thought to be restricted to the hematopoietic system, it is now known that c-myb is also expressed in certain non-hematopoietic tissues. 9 In particular, c-myb has a role in the proliferation of the progenitor cells in the colonic crypts. 10 The c-Myb protein exerts its biological functions as a transcription factor. Consequently, a large number of genes have been shown to be regulated by c-Myb, including genes involved in proliferation, cell survival and differentiation. [11] [12] [13] One of the most strongly activated Myb target genes is the chicken myb-inducible myeloid-specific gene-1 (mim-1), originally identified by Ness et al.
14 Recent work has shown that mim-1 expression is regulated by Myb in a complex manner, involving several cis-acting DNA-elements, as well as several cooperating proteins. [15] [16] [17] [18] [19] Although myb was originally identified as the oncogene of the avian myeloblastosis virus, it was suspected that c-myb is also involved in the development of human cancer. Recent work has indeed provided strong evidence that deregulated c-myb expression has a role in the development of certain leukemias, and of breast and colon tumors. Suppression of c-Myb-induced gene activation might therefore be a valuable therapeutic strategy. 2 Here, we have investigated the potential of sesquiterpene lactones (STLs), a class of natural products that possess a variety of biological activities and have been identified as active constituents of various medicinal plants, [20] [21] [22] to inhibit the activation of Myb-inducible genes. We have generated a fluorescence-based cell system that allows screening of STLs and other compounds for their ability to suppress the activation of a Myb-inducible reporter gene. By using this system, we have identified the STL mexicanin-I as the first cell-permeable, low-molecular-weight inhibitor of Myb-induced gene expression.
Materials and methods

Cells
HD11-E and HD11-C3 are stable transfectants of the myelomonocytic chicken cell line HD11, expressing doxycyclin-inducible v-Myb or chicken c-Myb, respectively. 19, 23 HD11-C3-GFP1 cells were generated by transfecting a reporter gene, carrying the enhancer and promoter of the mim-1 gene 17 and the coding region for enhanced green fluorescent protein (eGFP) into HD11-C3 cells, followed by selection of stable transfectants. Quantitative measurement of the fluorescence intensity of HD11-C3-GFP1 cells was performed using a fluorescence microplate reader. QT6 is a line of quail fibroblasts. BM2 cells are transformed by AMV and express the v-Myb protein. K562, HL60 and U937 are human leukemia cell lines, MCF7 is a human breast cancer cell line, and HEK293 is a human embryo kidney cell line. Acute myeloid leukemia (AML) blast cells were obtained from the bone marrow of patients diagnosed with AML at the University of Münster Hospital. Blasts were enriched (usually 490%) by density centrifugation. CD34 þ hematopoietic progenitor cells were isolated by magnetic cell sorting from leukapheresis products of healthy donors undergoing harvest for allogeneic stem cell transplantation. All patients and donors provided written consent, and all studies were approved by the local ethics committee.
Sesquiterpene lactones
Mexicanin-I and helenalin were isolated from Arnica species, and 11b,13-dihydroparthenolide was a gift from NH Fischer (Department of Chemistry, Louisiana State University, Baton Rouge, USA). Isoalantolactone was isolated from the roots of Inula helenium (Asteraceae). 24 Parthenolide, dehydrocostus lactone, 2-cyclopentene-1-one and a-methylene-g-butyrolactone were obtained from Sigma-Aldrich (Munich, Germany). The purity of all compounds was 490% by HPLC and/or 1 H-NMR. 10 mM stock solutions were prepared in DMSO.
Transfections
QT6 fibroblasts were transfected by calcium-phosphate co-precipitation, and reporter gene activities were analyzed as described. 17 The luciferase reporter gene pGL4-5xMRE(GG)-Myc contains five tandem copies of an Myb-binding site upstream of the human c-myc core promoter. 25 The b-galactosidase reporter gene pCMVb was from Clontech (Heidelberg, Germany). Expression vectors for v-Myb (pCDE26v-myb) and human c-Myb (pCIneo-HcM-HA) have been described. 23, 26 v-Myb C130A is a v-Myb mutant with a substitution of cysteine 130 by alanine. The expression of endogenous mim-1 mRNA in HD11 cells transiently transfected with wild-type or C130A mutant v-Myb expression vectors was analyzed by northern blotting as described before. 15 
RNA analysis
Preparation of polyadenylated RNA and northern blotting of mim-1, lysozyme and GAPDH mRNAs were performed as described. 15 For real-time PCR analysis total RNA was isolated and reverse transcribed using commercial kits (Fermentas, St Leon Roth, Germany). The following primers were used for real-time PCR: b-actin mRNA: 
Cell proliferation assay
Cells were grown for 24 h in the presence or absence of STLs, followed by labeling with 3 H-thymidine for 1 h. The cells were then lysed, and the radioactivity incorporated into trichloracetic acid (TCA)-precipitable material was determined in a scintillation counter.
Colony assays
AML blasts and CD34
þ progenitor cells were seeded in growth factor-supplemented methylcellulose (Stem cell Technologies, Grenoble, France). CD34 þ cells were seeded as 10 3 cells per dish, whereas AML blasts were seeded as 10 5 cells per dish. All experiments were performed in triplicate. After incubation at 37 1C, colonies with more than 50 agglomerated cells were counted on day 7.
Electrophoretic mobility shift assay
Nuclear extracts were prepared and electrophoretic mobility shift experiments were carried out as described. 27 
Results
The STL parthenolide inhibits the activation of the mim-1 gene by v-Myb Kawasaki et al. 28 have recently investigated the inhibitory effects of the STL parthenolide on a prostate cancer cell line. They identified several potential targets of parthenolide, one of which was the transcription factor c-Myb. We therefore became interested in studying the effects of parthenolide and other STLs on Myb activity in more detail. To investigate whether parthenolide affects the activation of Myb target genes by Myb, we used the chicken macrophage cell line HD11-E, which was engineered to express a viral version of the Myb protein (v-Myb) in a doxycyclin-inducible manner. 23 These cells show a very strong increase of the expression of several endogenous Myb target genes when Myb expression is induced by doxycyclin, 23 and therefore are a suitable test system to assess the effect of parthenolide on the activity of Myb in a physiological context. The expression of the mim-1 is an extremely sensitive measure of the Myb activity in these cells, because the gene is completely silent in the absence of Myb and reaches very high expression levels in its presence. 14 Figure 1a shows that parthenolide moderately inhibited the activation of mim-1 expression by v-Myb, demonstrating that parthenolide interferes with the activation of a target gene by v-Myb. Figure 1b confirms the induction of v-Myb expression by doxycyclin.
Parthenolide contains a highly reactive a-methylene-g-lactone group (for the chemical structure of parthenolide, see Figure 1d ) that can form covalent bonds with thiol groups of cysteine residues by a chemical reaction known as Michael-type addition. 29 The a-methylene-g-lactone group has been shown to be responsible for some of the biological effects of parthenolide. 30 To investigate the role of this functional group in the suppression of Myb activity, we compared the inhibitory 
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T Bujnicki et al potentials of parthenolide and 11b,13-dihydroparthenolide, in which the methylene group is reduced to a methyl group. Figure 1c shows that 11b,13-dihydroparthenolide was unable to inhibit Myb-dependent mim-1 expression, supporting the notion that the a-methylene-g-lactone group is critical for the inhibitory activity of parthenolide, and demonstrating the specificity of the inhibitory effect.
A screening system for Myb inhibitors
As a-methylene-g-lactone groups are common elements in various natural STLs, we were interested in exploring the effects of a larger panel of such compounds on Myb-induced gene expression. We therefore generated a fluorescence-based screening system that would allow us to examine the inhibitory potential of a larger number of compounds in a simple assay. We first constructed a reporter gene with the coding region of eGFP placed downstream of the promoter and enhancer of the mim-1 gene (see the top portion of Figure 2a) . It was previously shown that the cooperation of both cis-elements is responsible for the strong activation of the mim-1 gene by Myb. 17, 19 We then transfected the mim-1/eGFP reporter into the cell line HD11-C3, followed by selection of stable transfectants. HD11-C3 cells are similar to HD11-E cells except that they express chicken c-Myb in a doxycyclin-inducible manner. Figures 2b and c show that HD11-C3-GFP1 cells express c-Myb and mim-1 mRNA in the presence but not in the absence of doxycyclin. Furthermore, eGFP expression was increased after doxycyclin treatment as shown by fluorescence microscopy (Figure 2a) . Quantification of the fluorescence intensity showed that the inhibitory effect of parthenolide and the lack of inhibitory activity of 11b,13-dihydroparthenolide were recapitulated in the HD11-C3-GFP1 cells (see the two upper left panels of Figure 3 ). We then used these cells to examine the ability of a panel of about 30 different STLs to inhibit the activation of the reporter gene by c-Myb. We found that mexicanin-I, a STL isolated from Helenium mexicanum, 31,32 is a potent inhibitor of the Myb-induced activation of the reporter gene ( Figure 3 ). Mexicanin-I showed significant inhibition of the Myb-induced reporter gene activity already at concentrations of 1-3 mM. The STL helenalin, a stereoisomer of mexicanin-I, had similar inhibitory activity as mexicanin-I. Among the other compounds tested, isoalantolactone and dehydrocostuslactone showed weak inhibitory activity. Mexicanin-I and helenalin possess two a,b-unsaturated carbonyl groups (highlighted in Figure 3 ), which are highly reactive towards the thiol groups of cysteine residues, leading to the formation of covalent adducts. 21 To address whether the strong inhibitory effect exerted by mexicanin-I and helenalin might be caused by rather nonspecific alkylation reactions, we examined the inhibitory activity of two compounds, 2-cyclopentene-1-one and a-methylene-bbutyrolactone, whose structures correspond to either of the two reactive ring systems of mexicanin-I. Both compounds had no significant effect even at the highest concentration tested (Figure 3 ). This underlines the specificity of the inhibitory effect exerted by mexicanin-I.
Mexicanin-I is a potent inhibitor of Myb-induced gene expression
Having identified mexicanin-I as a potent inhibitor in our screening system, we wished to ascertain that mexicanin-I also 
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inhibits Myb activity when assayed under more physiological conditions. We therefore turned again to the HD11-E cell line to confirm the effect of mexicanin-I on the expression of the endogenous mim-1 gene. Figure 4a shows that mexicanin-I strongly suppressed the activation of the endogenous mim-1 gene by doxycyclin-inducible v-Myb. Mexicanin-I had no effect on the expression of Myb itself, consistent with the notion that mexicanin-I inhibits the activity and not the expression or the stability of Myb. We also used a transiently transfected luciferase reporter gene containing an array of five Myb binding sites to confirm the inhibitory effect of mexicanin-I (Figure 4b ). Similar inhibitory effects were observed in c-Myb-expressing HD11-C3 cells (Figure 4c) , showing that mexicanin-I inhibits vMyb, as well as c-Myb. Figure 4c also shows that mexicanin-I suppressed the activation of the lysozyme gene, another wellcharacterized Myb target gene, 23, 33 demonstrating that the inhibitory effect of mexicanin-I was not restricted to the mim-1 gene. Finally, we showed that the inhibitory effect was not due to a general cytotoxic effect of mexicanin-I at these concentrations, as demonstrated by a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide) assay (Figure 4d ). Taken together, the data illustrated in Figure 4 show that mexicanin-I is a potent inhibitor of Myb-inducible gene expression.
Previous work has shown that the Myb DNA-binding domain contains a cysteine (C130) residue, which is essential for sequence-specific DNA-binding by Myb. 34 To investigate whether mexicanin-I inhibits the DNA-binding activity of Myb, we performed electrophoretic mobility shift assays using nuclear extracts from BM2 cells, which abundantly express v-Myb. As shown in Figure 5a , treatment with mexicanin-I had no effect on the specific DNA-binding activity of v-Myb, suggesting that mexicanin-I does not act via cysteine 130. To confirm this, we generated a mutant in which cysteine 130 was replaced by alanine. As shown in Figure 5c , activation of mim-1 expression by the C130A mutant was inhibited by mexicanin-I, demonstrating that cysteine 130 is not the target for mexicanin-I.
Mexicanin-I inhibits the expression of c-Myb target genes in the human leukemia cell line K562, and the proliferation of human leukemia cells
We were interested to know whether mexicanin-I also affects the activation of Myb-target genes in human cells. To address this question we initially performed reporter gene experiments using an expression vector for human c-Myb. As shown in Figure 6a , mexicanin-I also suppressed the activation of a mim-1 reporter gene by human c-Myb. To assess the effect of mexicanin-I on the expression of endogenous Myb target genes in human cells we used the human leukemia cell line K562. By applying stringent criteria, including chromatin immunoprecipitation and siRNA knockdown studies, Berge et al. 13 have shown that the c-myc and adenosine deaminase genes are bona fide target genes of c-Myb in K562 cells. We therefore studied the effect of mexicanin-I on the expression of these genes by real-time PCR. We found that the expression of both Myb target genes was suppressed by mexicanin-I in a dose-dependent manner, whereas the expression of c-Myb was not affected (Figures 6b and c) . The extent of suppression of both the genes by mexicanin-I was similar to the suppression observed after knockdown of c-Myb with siRNA. 13 These experiments strongly suggested that mexicanin-I also inhibits human c-Myb dependent gene expression.
We also investigated the ability of mexicanin-I to inhibit the proliferation of human tumor cell lines. We used human leukemia cell lines (K562, HL60, U937) and a breast cancer line (MCF7), all of which express c-Myb, as well as a human embryo kidney line (HEK293), which lacks c-Myb expression. The proliferative activity was assessed by measuring the incorporation of radioactive thymidine into DNA. 
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shows that the proliferation of all c-Myb-expressing cell lines was strongly inhibited by mexicanin-I at concentrations between 1 and 3 mM, whereas the HEK293 cells were less sensitive. Microscopic inspection and analysis of the cells by a MTT assay showed that the cells died with increasing concentrations of mexicanin-I (data not shown). Finally, to begin to explore the effect of mexicanin-I on primary human cells we have performed colony formation assays of CD34 þ cells isolated from healthy donor leukapheresis products and of leukemic blasts from several AML patients. Figure 6e shows that colony formation of three different batches of CD34 þ cells was only weakly inhibited after exposure to 0.5 mM mexicanin-I. Also, no effect was observed in total bone marrow colony assays from a healthy donor. AML blasts do not consistently form colonies when plated in methylcellulose in vitro. We therefore chose blasts from five AML patients that were known to form colonies. In these experiments, 10 5 cells were seeded for each 35 mm dish. Mexicanin at a low concentration (0.5 mM) strongly inhibited the colony growth of three AML patients. Blasts from the two other patients were resistant. One of the patients with resistant blasts presented with a secondary AML after preceding myelodysplastic syndrome and a complex karyotype. No other association was observed between clinical patient characteristics and the mexicanin-I response.
Discussion
STLs constitute a large and structurally diverse class of secondary plant metabolites that carry a-methylene-g-lactone groups as common structural elements and display various biological activities. [20] [21] [22] STLs are the active constituents of a variety of medicinal plants used in traditional medicine for the treatment of inflammatory diseases. 20 In recent years, the anti-cancer properties of various STLs have attracted interest, and extensive research has been carried out to characterize the anti-cancer activity and the potential chemotherapeutic application of STLs. [35] [36] [37] On the molecular level, the effects of STLs on cell signaling pathways such as nuclear transcription factorkappaB (NF-kB) and mitogen-activated protein kinases have been intensely studied. [38] [39] [40] Previous work has implicated c-Myb as a potential therapeutic target in several types of human tumors, including colon cancer, breast cancer and leukemia. 3 Studies employing antisense oligodeoxynucleotides or dominantnegative forms of Myb have shown that Myb activity is essential for the continued proliferation of AML and chronic myeloid leukemia (CML) cells. 41, 42 Although c-Myb in most cases does not appear to have a causal role in the development of these leukemias, AML and CML cells seem to be addicted to Myb, and show greater sensitivity to c-Myb inhibition than their normal counterparts. 41, 42 Alterations of the c-Myb gene occur in subsets of T-cell acute lymphoblastic leukemias, where specific translocations or duplications involving c-Myb lead to increased c-Myb expression, and contribute to the leukemic phenotype of Inhibition of Myb activity T Bujnicki et al the tumor cells. 43, 44 Outside the hematopoietic system c-Myb is frequently over-expressed in colorectal cancer, and c-Myb expression correlates with poor prognosis for patients with this type of cancer. 45, 46 c-Myb is also expressed in a significant percentage of estrogen-receptor-positive breast cancer cells. 47, 48 Initial work has shown that blocking c-myb expression with shRNAs suppressed the estrogen-dependent proliferation of these cells, indicating a dependence of estrogen-receptorpositive breast cancer cells on Myb. 48 However, a more complex picture of the role of c-myb in breast cancer has emerged recently, due to the identification of breast cancer subtypes in which high c-myb expression is correlated with good prognosis 49 or in which c-myb may actually have tumor suppressive functions. 50 Finally, a recurrent fusion of Myb to transcription factor NF1B has been detected in carcinomas of the breast, and head and neck. 51 Taken together, these 
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T Bujnicki et al observations strongly reinforce the potential value of c-Myb as a therapeutic target. Efforts to target c-Myb so far have mainly concentrated on suppressing the expression of c-myb mRNA by using specific antisense oligodeoxynucleotides or siRNAs. 41, 52 These procedures have proven useful in cells cultivated in vitro, however; their application requires specific strategies for introducing the inhibitory nucleic acids into the cells. The work reported here identifies the STL mexicanin-I as the first cell-permeable compound that significantly suppresses the activation of c-Myb target genes at low micromolar concentrations.
The presence of a,b-unsaturated carbonyl groups suggested that the inhibitory effect of mexicanin-I might be due to covalent binding to one of the several cysteine residues present in the c-Myb protein or in a protein closely cooperating with Myb required for its activity. This would be supported by the fact that 11b,13-dihydroparthenolide, in which the reactive methylene lactone moiety is removed, was essentially inactive, whereas parthenolide, possessing this structure element showed significant activity. However, the observation (see Figure 3) that two model compounds, 2-cyclopentene-1-one and a-methylene-gbutyrolactone, representing the highly reactive ring systems of mexicanin-I had no inhibitory effect even at high concentrations also suggests that the sesquiterpenoid skeleton of these compounds is of major importance for the observed inhibitory effects. At present, we do not know the molecular mechanism by which mexicanin-I affects the c-Myb activity. We can exclude that the cysteine located within the DNA-binding domain is the target for mexicanin-I; however there are several additional cysteines in the transactivation region of Myb that might be involved. Moreover, it cannot be excluded that mexicanin-I exerts its activity by non-covalent interactions. Clearly, further work is required to understand the molecular mechanism by which mexicanin-I exerts its inhibitory activity. Nevertheless, our data provide initial evidence that mexicanin-I might differentially affect the growth of normal versus leukemic hematopoietic cells, at least for a fraction of AML patients. The identification of mexicanin-I as the first cell-permeable, low-molecular-weight inhibitor acting in the Myb pathway highlights mexicanin-I or related STLs as possible lead compounds for the development of therapeutic inhibitors of Myb.
